Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies
Abstract Background Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study w...
Gespeichert in:
| Veröffentlicht in: | European journal of internal medicine 2014-06, Vol.25 (5), p.482-484 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 484 |
|---|---|
| container_issue | 5 |
| container_start_page | 482 |
| container_title | European journal of internal medicine |
| container_volume | 25 |
| creator | Biondo, M.I Germano, V Pietrosanti, M Canzoni, M Marignani, M Stroffolini, T Salemi, S D'Amelio, R |
| description | Abstract Background Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study was to evaluate the safety of anti-TNFα therapy in anti-HBc positive/HBsAg negative subjects with rheumatoid arthritis (RA) and spondyloarthropathy (SpA). Methods All consecutive HBsAg negative RA and SpA outpatients referring to the Immuno-Rheumatology Institute at the S. Andrea hospital, Sapienza, University of Rome who had to undergo anti-TNFα therapy. Results Among the 169 enrolled subjects, 20 (12%) were potential occult HBV carriers (anti-HBc positive, HBsAg and HBV-DNA negative patients with or without anti-HBs). During the follow-up (mean ± SD 45 ± 22 months), aminotransferases and HBV-DNA, tested every two and six months respectively, did not change. Conclusion This study confirms the substantial safety of anti-TNFα therapy in potential occult HBV carriers RA and SpA patients. |
| doi_str_mv | 10.1016/j.ejim.2013.11.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1530957711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0953620514000144</els_id><sourcerecordid>1530957711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-2cec4b7a9e535bd4b97cee39436e7613f920b562bcbade87d19eebc36ff86633</originalsourceid><addsrcrecordid>eNp9kk2O1DAQhS0EYnoGLsACeckmwRU7fxJCghEMSC2xYPaW41TUziRxYzuN-iRcl4p6YMGClUul75Vc7xVjr0DkIKB6O-Y4ujkvBMgcIBegnrAdNHWbiaZonrKdaEuZVYUor9h1jKMQUAshn7OrQqm2rCq5Y7_2xj5wP_ADHk1yyUX-kZ9cWCMPaGxyJ-r6hZshYeBmSS5L6-zXwBe0wUfiB8J84In4NOOSuFv40SeqnJm4t3adErcmBIch8p8uHbg9BL84S-QwmXk2pD9zExK16RcHh_EFezaYKeLLx_eG3X_-dH_7Jdt_u_t6-2GfWQWQssKiVV1tWixl2fWqa2uLKFslK6wrkENbiK6sis52psem7qFF7KyshqGh_eUNe3MZewz-x4ox6dlFi9NkFvRr1FBKMrGuAQgtLui2dgw46GNwswlnDUJveehRb3noLQ8NoCkPEr1-nL92M_Z_JX8CIODdBUBa8kQO6WgdLhZ7F9Am3Xv3__nv_5HbyZGzZnrAM8aRglrIPg06Flro79tFbAcBStA1KCV_A4putgo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1530957711</pqid></control><display><type>article</type><title>Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Biondo, M.I ; Germano, V ; Pietrosanti, M ; Canzoni, M ; Marignani, M ; Stroffolini, T ; Salemi, S ; D'Amelio, R</creator><creatorcontrib>Biondo, M.I ; Germano, V ; Pietrosanti, M ; Canzoni, M ; Marignani, M ; Stroffolini, T ; Salemi, S ; D'Amelio, R</creatorcontrib><description>Abstract Background Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study was to evaluate the safety of anti-TNFα therapy in anti-HBc positive/HBsAg negative subjects with rheumatoid arthritis (RA) and spondyloarthropathy (SpA). Methods All consecutive HBsAg negative RA and SpA outpatients referring to the Immuno-Rheumatology Institute at the S. Andrea hospital, Sapienza, University of Rome who had to undergo anti-TNFα therapy. Results Among the 169 enrolled subjects, 20 (12%) were potential occult HBV carriers (anti-HBc positive, HBsAg and HBV-DNA negative patients with or without anti-HBs). During the follow-up (mean ± SD 45 ± 22 months), aminotransferases and HBV-DNA, tested every two and six months respectively, did not change. Conclusion This study confirms the substantial safety of anti-TNFα therapy in potential occult HBV carriers RA and SpA patients.</description><identifier>ISSN: 0953-6205</identifier><identifier>EISSN: 1879-0828</identifier><identifier>DOI: 10.1016/j.ejim.2013.11.014</identifier><identifier>PMID: 24495663</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Anti-TNFα ; Antirheumatic Agents - immunology ; Antirheumatic Agents - pharmacology ; Antirheumatic Agents - therapeutic use ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - immunology ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Carrier State - blood ; Chronic Disease ; Female ; HBcAb-positive ; HBV reactivation ; Hepatitis B Antibodies - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - physiology ; Humans ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Internal Medicine ; Male ; Middle Aged ; Rheumatic diseases ; Spondylarthropathies - drug therapy ; Spondylarthropathies - immunology ; Spondylitis, Ankylosing - drug therapy ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Virus Activation - drug effects</subject><ispartof>European journal of internal medicine, 2014-06, Vol.25 (5), p.482-484</ispartof><rights>European Federation of Internal Medicine.</rights><rights>2014 European Federation of Internal Medicine.</rights><rights>Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-2cec4b7a9e535bd4b97cee39436e7613f920b562bcbade87d19eebc36ff86633</citedby><cites>FETCH-LOGICAL-c411t-2cec4b7a9e535bd4b97cee39436e7613f920b562bcbade87d19eebc36ff86633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejim.2013.11.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24495663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Biondo, M.I</creatorcontrib><creatorcontrib>Germano, V</creatorcontrib><creatorcontrib>Pietrosanti, M</creatorcontrib><creatorcontrib>Canzoni, M</creatorcontrib><creatorcontrib>Marignani, M</creatorcontrib><creatorcontrib>Stroffolini, T</creatorcontrib><creatorcontrib>Salemi, S</creatorcontrib><creatorcontrib>D'Amelio, R</creatorcontrib><title>Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies</title><title>European journal of internal medicine</title><addtitle>Eur J Intern Med</addtitle><description>Abstract Background Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study was to evaluate the safety of anti-TNFα therapy in anti-HBc positive/HBsAg negative subjects with rheumatoid arthritis (RA) and spondyloarthropathy (SpA). Methods All consecutive HBsAg negative RA and SpA outpatients referring to the Immuno-Rheumatology Institute at the S. Andrea hospital, Sapienza, University of Rome who had to undergo anti-TNFα therapy. Results Among the 169 enrolled subjects, 20 (12%) were potential occult HBV carriers (anti-HBc positive, HBsAg and HBV-DNA negative patients with or without anti-HBs). During the follow-up (mean ± SD 45 ± 22 months), aminotransferases and HBV-DNA, tested every two and six months respectively, did not change. Conclusion This study confirms the substantial safety of anti-TNFα therapy in potential occult HBV carriers RA and SpA patients.</description><subject>Aged</subject><subject>Anti-TNFα</subject><subject>Antirheumatic Agents - immunology</subject><subject>Antirheumatic Agents - pharmacology</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - immunology</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Carrier State - blood</subject><subject>Chronic Disease</subject><subject>Female</subject><subject>HBcAb-positive</subject><subject>HBV reactivation</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - physiology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Rheumatic diseases</subject><subject>Spondylarthropathies - drug therapy</subject><subject>Spondylarthropathies - immunology</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Virus Activation - drug effects</subject><issn>0953-6205</issn><issn>1879-0828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kk2O1DAQhS0EYnoGLsACeckmwRU7fxJCghEMSC2xYPaW41TUziRxYzuN-iRcl4p6YMGClUul75Vc7xVjr0DkIKB6O-Y4ujkvBMgcIBegnrAdNHWbiaZonrKdaEuZVYUor9h1jKMQUAshn7OrQqm2rCq5Y7_2xj5wP_ADHk1yyUX-kZ9cWCMPaGxyJ-r6hZshYeBmSS5L6-zXwBe0wUfiB8J84In4NOOSuFv40SeqnJm4t3adErcmBIch8p8uHbg9BL84S-QwmXk2pD9zExK16RcHh_EFezaYKeLLx_eG3X_-dH_7Jdt_u_t6-2GfWQWQssKiVV1tWixl2fWqa2uLKFslK6wrkENbiK6sis52psem7qFF7KyshqGh_eUNe3MZewz-x4ox6dlFi9NkFvRr1FBKMrGuAQgtLui2dgw46GNwswlnDUJveehRb3noLQ8NoCkPEr1-nL92M_Z_JX8CIODdBUBa8kQO6WgdLhZ7F9Am3Xv3__nv_5HbyZGzZnrAM8aRglrIPg06Flro79tFbAcBStA1KCV_A4putgo</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Biondo, M.I</creator><creator>Germano, V</creator><creator>Pietrosanti, M</creator><creator>Canzoni, M</creator><creator>Marignani, M</creator><creator>Stroffolini, T</creator><creator>Salemi, S</creator><creator>D'Amelio, R</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies</title><author>Biondo, M.I ; Germano, V ; Pietrosanti, M ; Canzoni, M ; Marignani, M ; Stroffolini, T ; Salemi, S ; D'Amelio, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-2cec4b7a9e535bd4b97cee39436e7613f920b562bcbade87d19eebc36ff86633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Anti-TNFα</topic><topic>Antirheumatic Agents - immunology</topic><topic>Antirheumatic Agents - pharmacology</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - immunology</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Carrier State - blood</topic><topic>Chronic Disease</topic><topic>Female</topic><topic>HBcAb-positive</topic><topic>HBV reactivation</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - physiology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Rheumatic diseases</topic><topic>Spondylarthropathies - drug therapy</topic><topic>Spondylarthropathies - immunology</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Virus Activation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biondo, M.I</creatorcontrib><creatorcontrib>Germano, V</creatorcontrib><creatorcontrib>Pietrosanti, M</creatorcontrib><creatorcontrib>Canzoni, M</creatorcontrib><creatorcontrib>Marignani, M</creatorcontrib><creatorcontrib>Stroffolini, T</creatorcontrib><creatorcontrib>Salemi, S</creatorcontrib><creatorcontrib>D'Amelio, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biondo, M.I</au><au>Germano, V</au><au>Pietrosanti, M</au><au>Canzoni, M</au><au>Marignani, M</au><au>Stroffolini, T</au><au>Salemi, S</au><au>D'Amelio, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies</atitle><jtitle>European journal of internal medicine</jtitle><addtitle>Eur J Intern Med</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>25</volume><issue>5</issue><spage>482</spage><epage>484</epage><pages>482-484</pages><issn>0953-6205</issn><eissn>1879-0828</eissn><abstract>Abstract Background Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study was to evaluate the safety of anti-TNFα therapy in anti-HBc positive/HBsAg negative subjects with rheumatoid arthritis (RA) and spondyloarthropathy (SpA). Methods All consecutive HBsAg negative RA and SpA outpatients referring to the Immuno-Rheumatology Institute at the S. Andrea hospital, Sapienza, University of Rome who had to undergo anti-TNFα therapy. Results Among the 169 enrolled subjects, 20 (12%) were potential occult HBV carriers (anti-HBc positive, HBsAg and HBV-DNA negative patients with or without anti-HBs). During the follow-up (mean ± SD 45 ± 22 months), aminotransferases and HBV-DNA, tested every two and six months respectively, did not change. Conclusion This study confirms the substantial safety of anti-TNFα therapy in potential occult HBV carriers RA and SpA patients.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>24495663</pmid><doi>10.1016/j.ejim.2013.11.014</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0953-6205 |
| ispartof | European journal of internal medicine, 2014-06, Vol.25 (5), p.482-484 |
| issn | 0953-6205 1879-0828 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1530957711 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Anti-TNFα Antirheumatic Agents - immunology Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - immunology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Carrier State - blood Chronic Disease Female HBcAb-positive HBV reactivation Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - blood Hepatitis B virus - physiology Humans Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Internal Medicine Male Middle Aged Rheumatic diseases Spondylarthropathies - drug therapy Spondylarthropathies - immunology Spondylitis, Ankylosing - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors Virus Activation - drug effects |
| title | Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T09%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20hepatitis%20B%20virus%20reactivation%20after%20anti-tumour%20necrosis%20factor%20treatment%20in%20potential%20occult%20carriers%20with%20chronic%20inflammatory%20arthropathies&rft.jtitle=European%20journal%20of%20internal%20medicine&rft.au=Biondo,%20M.I&rft.date=2014-06-01&rft.volume=25&rft.issue=5&rft.spage=482&rft.epage=484&rft.pages=482-484&rft.issn=0953-6205&rft.eissn=1879-0828&rft_id=info:doi/10.1016/j.ejim.2013.11.014&rft_dat=%3Cproquest_cross%3E1530957711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1530957711&rft_id=info:pmid/24495663&rft_els_id=S0953620514000144&rfr_iscdi=true |